Mendra

Mendra is a biopharmaceutical company founded by veterans of BioMarin Pharmaceutical and Escient Pharmaceuticals to modernize rare disease drug development. The company leverages artificial intelligence to address long-standing challenges in patient identification, clinical trial enrollment, data curation, and global commercialization for diseases with high unmet medical need. Mendra plans to acquire and develop rare disease assets, combining deep domain expertise with AI-driven capabilities across asset selection, clinical development, and global commercialization to accelerate access to innovative treatments for underserved patient populations. The company launched in January 2026 with an $82 million Series A co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Wing VC.